



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Miao and Kay
APPLICATION NO.: 09/884,901
FILED: June 18, 2001
FOR: LIVER-SPECIFIC GENE EXPRESSION
CASSETTES, AND METHODS OF USE

EXAMINER: Burkhart
ART UNIT: 1633
CONF. NO: 1704

Declaration of Carol H. Miao and Mark A. Kay

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

We, Carol H. Miao and Mark A. Kay, declare and affirm as follows:

1. We are co-inventors of the subject matter described and claimed in U.S. Patent Application No. 09/884,901, filed June 18, 2001 entitled LIVER-SPECIFIC GENE EXPRESSION CASSETTES, AND METHODS OF USE.
2. The subject matter as presently claimed relates to an expression cassette for expressing human Factor IX. The expression cassette is comprised of a hepatic locus control element, a hepatic promoter, a Factor IX coding sequence, a Factor IX Intron A, and a polyadenylation signal. In some embodiments, the cassette additionally comprises a 3' untranslated region.
3. An expression cassette previously invented by Dr. Kay is described in U.S. Patent No. 6,936,243, issued to Snyder *et al.* This previously described cassette included a promoter, a Factor IX coding sequence, and a polyadenylation signal.

4. Features of the presently claimed expression cassette that are not earlier invented by Dr. Kay are joint contributions by both of us.
5. For example, the hepatic locus control element in the claimed expression cassette was a joint contribution by both of us.
6. By way of another example, inclusion of the Factor IX Intron A, and the optional 3' untranslated region, in the claimed expression cassette were contributed by both of us.
7. By way of another example, the discovery that the claimed expression cassette absent a viral vector achieves long term expression of Factor IX *in vivo* was an inventive contribution of both of us. This discovery is currently set forth, for example, in claims 2-3, 36-38, and 40-42.

We declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the Unites States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,

5/24/2007
Date

Carol H. Miao
Carol H. Miao

Date

Mark A. Kay

4. Features of the presently claimed expression cassette that are not earlier invented by Dr. Kay are joint contributions by both of us.
5. For example, the hepatic locus control element in the claimed expression cassette was a joint contribution by both of us.
6. By way of another example, inclusion of the Factor IX Intron A, and the optional 3' untranslated region, in the claimed expression cassette were contributed by both of us.
7. By way of another example, the discovery that the claimed expression cassette absent a viral vector achieves long term expression of Factor IX *in vivo* was an inventive contribution of both of us. This discovery is currently set forth, for example, in claims 2-3, 36-38, and 40-42.

We declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,

Date


Carol H. Miao

5/24/07
Date


Mark A. Kay



Fig. 2A.






Fig. 2B.



-continued

gagaaggggtg cagcaggctc aaaggcataa gtcattccaa tcagccaact aagttgtcct 1260
 tttctggttt cgtgttcacc atggaacatt ttgattatag ttaatccttc tatcttgaat 1320
 cttctagaga gttgctgacc aactgacgta tgtttccctt tgtgaattaa taaactggtg 1380
 ttctggttca taccttggct ttttgggat tccattgatg tgaatcagtc accctgtatt 1440
 tgatgatgca tgggactact gacaaaatca ctctgaccct gccaaagtgc tgccttctcc 1500
 tgccccaacc tcacccccag ccaggcctca ctcttgctag ttcctttagt tcttttagtc 1560
 aatataattt tgccttcgca tataagtata aataaacata tttttaaatt tcttgctgg 1620
 gccagtggtc tcacgcctat aatcccagca cttctggagg ccaaggtggg cggatcacct 1680
 gaggttagga gtttcaggcc aagctta 1707

<210> SEQ ID NO 8
 <211> LENGTH: 154
 <212> TYPE: DNA
 <213> ORGANISM: HomoSapien

<400> SEQUENCE: 8

gtttgggtgc tgcctctgaa gtccacactg aacaaacttc agcctactca tgcacctaaa 60
 atgggcaaac attgcaagca gcaaacagca aacacacagc cctccctgcc tgctgacctt 120
 ggagctgggg cagaggtcag agacctctct gggc 154

<210> SEQ ID NO 9
 <211> LENGTH: 328
 <212> TYPE: DNA
 <213> ORGANISM: Homo Sapien

<400> SEQUENCE: 9

caggctcaga ggcacacagg agtttctggg ctcaccctgc ccccttccaa cccctcagtt 60
 cccatcctcc agcagctgtt tgtgtgctgc ctctgaagtc cacactgaac aaacttcagc 120
 ctactcatgt ccctaaatg ggcacaactt gcaagcagca aacagcaaac acacagccct 180
 ccctgcctgc tgaccttggg gctggggcag aggtcagaga cctctctggg cccatgccac 240
 ctccaacatc cactcgacc cttggaattt cggtgagag gagcagaggt tgcctggcg 300
 tggtttaggt agtgtgagag ggtccggg 328

<210> SEQ ID NO 10
 <211> LENGTH: 8
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: HNF-1 Hepatic Nuclear Factor Binding Site
 Consensus Sequence

<400> SEQUENCE: 10

tgtaacag 8

<210> SEQ ID NO 11
 <211> LENGTH: 22
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: HNF-1 Alternative Hepatic Nuclear Factor
 Binding Site Consensus Sequence

-continued

Tyr Asn Ala Ala Ile Asn Lys Tyr Asn His Asp Ile Ala Leu Leu Glu
305 310 315 320

Leu Asp Glu Pro Leu Val Leu Asn Ser Tyr Val Thr Pro Ile Cys Ile
325 330 335

Ala Asp Lys Glu Tyr Thr Asn Ile Phe Leu Lys Phe Gly Ser Gly Tyr
340 345 350

Val Ser Gly Trp Gly Arg Val Phe His Lys Gly Arg Ser Ala Leu Val
355 360 365

Leu Gln Tyr Leu Arg Val Pro Leu Val Asp Arg Ala Thr Cys Leu Arg
370 375 380

Ser Thr Lys Phe Thr Ile Tyr Asn Asn Met Phe Cys Ala Gly Phe His
385 390 395 400

Glu Gly Gly Arg Asp Ser Cys Gln Gly Asp Ser Gly Gly Pro His Val
405 410 415

Thr Glu Val Glu Gly Thr Ser Phe Leu Thr Gly Ile Ile Ser Trp Gly
420 425 430

Glu Glu Cys Ala Met Lys Gly Lys Tyr Gly Ile Tyr Thr Lys Val Ser
435 440 445

Arg Tyr Val Asn Trp Ile Lys Glu Lys Thr Lys Leu Thr
450 455 460

<210> <SEQ-ID-NO-4>
<211> LENGTH: 771
<212> TYPE: DNA
<213> ORGANISM: HomoSapien

<400> SEQUENCE: 4

caggctcaga ggcacacagg agtttctggg ctcaccctgc ccccttccaa ccctcagtt 60

cccatcctcc agcagctgtt-tgtgtgctgc-ctctgaagtc-cacactgaac-aaacttcagc 120

ctactcatgt=ccctaaaatg-ggcaaacatt-gcaagcagca-aacagcaaac-acacagccct 180

ccttgctgc-tgacctgga-gctggggcag-aggtcagaga-cctctctggg-cccatgccac 240

ctccaacatc cactcgaccc cttggaatth cgggtggagag gagcagaggt tgcctggcg 300

tggttttaggt agtgtgagag ggtccgggtt caaaaccact tgctgggtgg ggagtgtca 360

gtaagtggct atgccccgac cccgaagcct gtttcccat ctgtacaatg gaaatgataa 420

agacgcccac ctgatagggt ttttgaggca aataaacatt tggttttttt gttttgttt 480

gttttgttt ttgagatgga gttttgctct gtcgcccagg ctggagtgca gtgacacaat 540

ctcatctcac cacaaccttc cctgcctca gcctccaag tagctgggat tacaagcatg 600

tgccaccaca cctggctaatt tttctattht tagtagagac gggtttctcc atgttggtca 660

gcctcagcct cccaagtaac tgggattaca ggctgtgcc accacaccg gctaattttt 720

tctatthttg acagggacgg ggttcacca tgttggtcag gctcctctag a 771

<210> SEQ ID NO 5
<211> LENGTH: 418
<212> TYPE: DNA
<213> ORGANISM: HomoSapien

<400> SEQUENCE: 5

ggatcttgc accagtggaa cagccactaa ggattctgca gtgagagcag agggccagct 60

aagtgttact ctcccagaga ctgtctgact cagcaccacc cctccacctt ggacacagga 120

-continued

```

cgctgtggtt tctgagccag gtacaatgac tcctttcggg aagtgcagtg gaagctgtac 180
actgccccag caaagcgtcc gggcagcgta ggcgggcgac tcagatccca gccagtggac 240
ttagcccctg tttgctctc cgataactgg ggtgacctg gttaatatc accagcagcc 300
tcccccggtg ccctctgga tccactgctt aaatcggac gaggacaggg ccctgtctcc 360
tcagcttcag gcaccaccac tgacctggga cagtgaatga tccccctgat ctgcggcc 418

```

```

<210> SEQ ID NO 6
<211> LENGTH: 282
<212> TYPE: DNA
<213> ORGANISM: Bos taurus

```

```

<400> SEQUENCE: 6

```

```

ccccggggat cagcctcgac tgtgccttct agttgccagc catctgttgt ttgccctcc 60
cccgtgcctt ccttgaccct ggaaggtgcc actcccactg tcctttccta ataaatgag 120
gaaattgcat cgcattgtct gagtaggtgt cattctatc tggggggtgg ggtggggcag 180
gacagcaagg gggaggattg ggaagacaat agcaggcatg ctggggatgc ggtgggctct 240
atggcttctg aggcggaaa g aaccagctgg ggctcagat cc 282

```

```

<210> SEQ ID NO 7
<211> LENGTH: 1707
<212> TYPE: DNA
<213> ORGANISM: HomoSapien

```

```

<400> SEQUENCE: 7

```

```

aatgaaagat gattttccaa ggtaattca ttggaattga aaattaacag ggcctctcac 60
taactaatca ctttcccatc ttttgtaga tttgaatata tacattctat gatcattgct 120
ttttctcttt acaggggaga atttcatatt ttacctgagc aaattgatta gaaaatgaa 180
ccactagagg aatataatg gttaggaaat tacagtcatt tctaagggc cagcccttga 240
caaaattgtg aagttaaatt ctccactctg tccatcagat actatggttc tccactatgg 300
caactaactc actcaatttt ccctccttag cagcattcca tcttcccgat cttctttgct 360
tctccaacca aaacatcaat gtttattagt tctgtatata gtacaggatc tttggtctac 420
tctatcacia gcccagtacc acactcatga agaaagaaca caggagtagc tgagaggcta 480
aaactcatca aaaacactac tccttttctc ctaccctatt cctcaatcct ttacctttc 540
caaatcccaa tccccaaatc agtttttctc tttcttactc cctctctccc ttttaccctc 600
catggtcggt aaaggagaga tggggagcat cattctgta tacttctgta cacagttata 660
catgtctatc aaaccagac ttgcttccat agtggagact tgcttttcag aacatagga 720
tgaagtaagg tgccctgaaa gtttggggga aaagtttctt tcagagagtt aagttatctt 780
atatatataa tatatatata aaatatataa tatacaatat aaatatatag tgtgtgtgtg 840
tatgctgtgt ttagacaca caccatata cacatataat ggaagcaata agccattcta 900
agagcttcta tggttatgga ggtctgacta ggcatgattt cacgaaggca agattggcat 960
atcattgtaa ctaaaaaagc tgacattgac ccagacatat tgtactcttt ctaaaaataa 1020
taataataat gctaacagaa agaagagaac cgttcgtttg caatctacag ctagtagaga 1080
ctttgaggaa gaattcaaca gtgtgtcttc agcagtgttc agagccaagc aagaagttga 1140
agttgcctag accagaggac ataagtatca tgtctccttt aactagcata cccggaagtg 1200

```


THIS OPINION WAS NOT WRITTEN FOR PUBLICATION

The opinion in support of the decision being entered today (1) was not written for publication in a law journal and (2) is not binding precedent of the Board.

Paper No. 17



UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE BOARD OF PATENT APPEALS
AND INTERFERENCES

Ex parte ALEXANDER R. POKORA
and MARK A. JOHNSON

Appeal No. 95-2444
Application 07/973,655¹

ON BRIEF

Before RONALD H. SMITH, Administrative Patent Judge and McKELVEY, Senior Administrative Patent Judge and HANLON, Administrative Patent Judge.

HANLON, Administrative Patent Judge.

DECISION ON APPEAL

This is an appeal under 35 U.S.C. § 134 from the final rejection of claims 1-12, all of the claims pending in the application.

The claims are directed to a process for treating a

¹ Application for patent filed November 9, 1992.

Appeal No. 95-2444
Application 07/973,655

lignocellulosic pulp with soybean peroxidase in the presence of a peroxide and removing lignin from the pulp. Appellants disclose that suitable pulps for the practice of the invention include kraft pulp (Specification, p.4). Claim 1 is illustrative of the subject matter on appeal and reads as follows:

1. A process which comprises treating a lignocellulosic pulp with soybean peroxidase in the presence of a peroxide, and removing lignin from said pulp.

The references relied upon by the examiner are:

Johnson et al. (Johnson)	5,147,793	Sep. 15, 1992
Vaherl et al. (Vaherl) (European Patent Application)	0 395 792	Nov. 7, 1990
Canadian Patent Application	2,019,411	Dec. 22, 1990

The following rejections are at issue in this appeal:

(1) Claim 1 is rejected under 35 U.S.C. § 102(a) or (e) as anticipated by or, in the alternative, under 35 U.S.C. § 103 as obvious over the '793 patent.²

(2) Claims 1-4, 6 and 9-12 are rejected under 35 U.S.C. § 103 as being unpatentable over Canadian patent application no.

² The examiner refers to U.S. Patent No. 5,147,793, as "Cyrus, Jr. et al." throughout the final Office action and the answer, and appellants refer to this same reference as "Johnson '793." We will refer to U.S. Patent No. 5,147,793 as "the '793 patent".

Appeal No. 95-2444
Application 07/973,655

2,019,411 in view of the '793 patent.

(3) Claims 7 and 8 are rejected under 35 U.S.C. § 103 as being unpatentable over Canadian patent application no. 2,019,411 in view of the '793 patent, and further in view of the admitted prior art (Specification, p.5, lines 20-22).

(4) Claim 5 is rejected under 35 U.S.C. § 103 as being unpatentable over Canadian patent application no. 2,019,411 in view of the '793 patent, and further in view of European patent application no. 395,792.

Grouping of claims

According to appellants, "[f]or purposes of this appeal, all claims stand or fall together" (Brief, p.3). Therefore, dependent claims 2-12 stand or fall with the patentability of independent claim 1.

Rejection of claim 1 under 35 U.S.C. § 102(a) or (e) or, in the alternative, under 35 U.S.C. § 103 over the '793 patent

The '793 patent discloses that soybean peroxidase is useful "in enzymatic bleaching of Kraft pulp" (col. 10, lines 44-45). The examiner maintains that this teaching either anticipates or renders claim 1 obvious (Answer, pp.2-3).

Appeal No. 95-2444
Application 07/973,655

Appellants argue that (Brief, pp.3-4):

Johnson '793 is not a proper reference to serve as a basis of rejection for the claims under 35 U.S.C. §102(a) or (e). The inventors, Mr. Pokora and Mr. Johnson, along with Mr. Cyrus, Jr. have submitted a Declaration under 37 C.F.R. §1.132 which states that they are the joint inventors of Johnson '793 and that Mr. Johnson and Mr. Pokora are the inventors of the process for using soybean peroxidase to bleach Kraft pulp described in the Johnson '793 patent. These Declarations eliminate Johnson '793 as prior art because they establish that the reference to bleaching Kraft pulp in Johnson '793 is not the disclosure or invention of another, but rather is the invention of Johnson and Pokora, the applicants.

The declaration under 37 CFR § 1.132 reads, in pertinent part, as follows:

We, Mark A. Johnson, Alexander R. Pokora and William L. Cyrus, Jr., declare and state the following:

(1) We are joint inventors of U.S. Patent No. 5,147,793;

(2) The subject matter relating to the use of soybean peroxidase in enzymatic bleaching of kraft pulp at column 10, lines 44-45 of U.S. Patent No. 5,147,793, but not claimed therein, is the invention of Mark A. Johnson and Alexander R. Pokora and is not the invention of William L. Cyrus, Jr.; and

(3) Mark A. Johnson and Alexander R. Pokora conceived of the subject matter

Appeal No. 95-2444
Application 07/973,655

disclosed and claimed in U.S. Patent
Application No. 07/973,655 prior to the
filing date of U.S. Patent No. 5,147,793.

The declaration was signed by the three patentees of the '793
patent, Mark A. Johnson, Alexander R. Pokora and William L.
Cyrus, Jr.³

The examiner maintains that the declaration fails to remove
the '793 patent as prior art under 35 U.S.C. § 102(a) and (e) for
the reason that (Answer, p.5):

[T]he claims of CYRUS, JR. ET AL call for the
"biocatalytic oxidation of an oxidizable
substrate". The claims are not limited to
the polymerization reactions of the Examples.
When CYRUS JR. ET AL is read in view of its
specification the claimed "biocatalytic
oxidation" would include the disclosed
"bleaching", and the claimed "oxidizable
substrate" would include the disclosed "kraft
pulp". Thus the claims of CYRUS JR. ET AL
would include bleaching of Kraft pulp which
includes the delignification (Kraft bleaching
and/or delignifying) of lignocellulosic
material (pulp), see the instant
specification, page 3, lines 18-22. Thus the
claimed subject matter of the instant
Application, was disclosed and claimed in
Patent No. 5,147,793.

We note at the outset that the declarants expressly state

³ Three copies of this declaration were received, one signed by Mark A. Johnson dated December 9, 1993, one signed by William L. Cyrus, Jr. dated December 13, 1993, and one signed by Alexander R. Pokora dated December 28, 1993.

Appeal No. 95-2444
Application 07/973,655

that "[t]he subject matter relating to the use of soybean peroxidase in enzymatic bleaching of kraft pulp at column 10, lines 44-45 of U.S. Patent No. 5,147,793" is not claimed therein (Declaration, ¶2). Claim 1 of the '793 patent recites a method for biocatalytic oxidation of an oxidizable substrate comprising (1) preparing a solution of the oxidizable substrate and (2) contacting the solution with soybean hulls in the presence of a peroxide. First, the treated lignocellulosic pulp in appellants' claim 1 is not in solution. Second, soybean hulls are not the same as soybean peroxidase, required in appellants' claim 1. Rather, soybean hulls are one of several elements used to produce soybean peroxidase ('793 patent, col. 12, line 46 through col. 13, line 3; appellants' specification, p.3, lines 22-24). Therefore, the same invention is not claimed in appellants' application and the '793 patent.

The declaration under 37 CFR § 1.132 is sufficient and removes the '793 patent as available prior art under 35 U.S.C. § 102(a) and (e). See MPEP § 716.10 (6th ed. Rev. 2, July 1996) ("When subject matter, disclosed but not claimed in a patent application issued jointly to S and another, is claimed in a later application filed by S, the joint patent is a valid reference available as prior art under 35 U.S.C. 102(a), (e), or

Appeal No. 95-2444
Application 07/973,655

(f) unless overcome by . . . an unequivocal declaration by S
under 37 CFR 1.132 that he or she conceived or invented the
subject matter disclosed in the patent."); see also In re DeBaun,
687 F.2d 459, 463, 214 USPQ 933, 936 (CCPA 1982); In re Katz, 687
F.2d 450, 215 USPQ 14 (CCPA 1982). Accordingly, we reverse the
rejections based on the '793 patent alone and the rejections
based on the '793 patent in combination with any other reference
or references.

The decision of the examiner is reversed.

REVERSED

RONALD H. SMITH)
Administrative Patent Judge)
)
)
)
) BOARD OF PATENT
FRED E. McKELVEY, Senior)
Administrative Patent Judge) APPEALS AND
)
) INTERFERENCES
)
ADRIENE LEPIANE HANLON)
Administrative Patent Judge)

Appeal No. 95-2444
Application 07/973,655

THOMPSON, HINE and FLORY
2000 Courthouse Plaza N.E.
P.O. Box 8801
Dayton, Ohio 45401-8801